Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

354,475 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/03/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/03/2020.
Displaying: 229 trials in your specialties ()
View trials across your selected specialties

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Relapsed Multiple Myeloma, Refractory Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Nivolumab, Drug: Ixazomib, Drug: Dexamethasone, Drug: Cyclophosphamide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Brief Summary

This research is being done to assess the effectiveness and safety of the combination of nivolumab with ixazomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Daratumumab Subcutaneous (SC) Administration, Drug: Recombinant Human Hyaluronidase [rHuPH20]) SC Administration

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Winship Cancer Institute Emory University, Atlanta, Georgia, United States

Brief Summary

The purpose of the study is to evaluate the pharmacokinetics and safety from the mixture of daratumumab and rHuPH20 prepared immediately before administration via Subcutaneous (SC) delivery (Part 1) and CF (co-formulated daratumumab and rHuPH20 preparation) administration via SC delivery of daratumumab (Part 2) and to evaluate the safety of Dara-CF 1800 milligram (mg) SC delivery without pre-dose and post-dose corticosteroids (Part 3).

BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Biological: PHE885

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Brief Summary

This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells will be investigated as a single agent in relapsed/refractory multiple myeloma

Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Daratumumab, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

AZ ST Jan hematology department, Bruges, Belgium

Brief Summary

This study is a Multicentre, Open-label, Phase II study of Daratumumab and Dexamethasone in MM patients. Eligible patients must have a symptomatic RRMM with a measurable disease, resistant or refractory to Bortezomib and Lenalidomide and Pomalidomide. There is no dose escalation phase, as the MAxiamal Tolerated Dose (MTD) and drug scheduling have already been determined in previous phase 1-2 dose escalation studies. There is no randomization.

Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Relapsed/Refractory Multiple Myeloma
View Full Trial
INTERVENTION

Biological: Adult differentiated autologous T-cells with anti-BCMA specificity

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Clinica Universidad de Navarra, Pamplona, Navarra, Spain

Brief Summary

To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.

NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Neoplasms
View Full Trial
INTERVENTION

Genetic: NY-ESO-1ᶜ²⁵⁹T cells, Drug: NY-ESO-1ᶜ²⁵⁹T in combination with pembrolizumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

GSK Investigational Site, Duarte, California, United States

Brief Summary

This study is intended for men and women at least 18 years of age who have relapsed and/or refractory multiple myeloma. This 2-arm randomized pilot study will test the safety, tolerability and efficacy of NY-ESO-1ᶜ²⁵⁹T alone (Arm 1) or in combination with pembrolizumab (Arm 2) in subjects who have the appropriate HLA-A2 marker, and whose bone marrow expresses the NY-ESO-1 and/or LAGE-1a protein. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors.

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Relapsed or Refractory Multiple Myeloma
View Full Trial
INTERVENTION

Biological: CAR2 Anti-CD38 A2 CAR-T Cells

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Mayo Clinic Florida, Jacksonville, Florida, United States

Brief Summary

The study is an open-label Phase 1 single dose-escalation safety study of CAR2 Anti-CD38 A2 CAR-T Cells in patients with Relapsed or Refractory Multiple Myeloma, who meet all other eligibility criteria.

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymp...
View Full Trial
INTERVENTION

Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Brief Summary

This is a phase I trial with pilot expansion of HLA-haploidentical or HLA-mismatched related donor nicotinamide expanded-natural killer (NAM-NK) cell based therapy for patients with relapsed or refractory multiple myeloma (MM) or relapsed/refractory CD20-positive non-Hodgkin lymphoma (NHL). The primary endpoint of the study is to determine the maximum tolerated dose (MTD) of NAM-NK cells while maintaining safety.

Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Combination Product: BCMA CART + huCART19, Combination Product: CART BCMA or CART BCMA + huCART19, Combination Product: Single-dose infusion of CART BCMA or CART BCMA + huCART19, Combination Product: BCMA CART + huCART19

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Univ. of Pennsylvania, Philadelphia, Pennsylvania, United States

Brief Summary

This is an open-label phase 1 study to assess the safety and pharmacodynamics of CART-BCMA, with or without huCART19, in patients responding to first- or second-line therapy for high-risk multiple myeloma. The regimen evaluated in this study is based on established safety of CARTBCMA demonstrated in UPCC 14415/IRB#822756 at dose of 5x108 cells, administered as split infusions, following cyclophosphamide 1.5 g/m2 in patients with relapsed/refractory myeloma. This study tests CART-BCMA (1) as consolidation of early therapy for multiple myeloma, (2) with addition of fludarabine to the lymphodepleting chemotherapy regimen, (3) in combination with huCART19, and (4) as a single rather than split-dose infusion.

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Relapsed/Refractory Multiple Myeloma
View Full Trial
INTERVENTION

Drug: AMG 701, Drug: Pomalidomide, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Research Site, Phoenix, Arizona, United States

Brief Summary

The primary purpose of the phase 1 part of the study is to evaluate safety and tolerability of AMG 701 monotherapy to identify the RP2D for AMG 701 monotherapy followed by a dose-confirmation part to gather further safety data for AMG 701 monotherapy at the RP2D in adult subjects with relapsed/refractory multiple myeloma (RRMM). In addition, this study will include a sequential dose exploration part to identify the RP2D of AMG 701 in combination with pomalidomide, with and without dexamethasone (AMG 701-P+/-d). Phase 2 will consist of the dose-expansion part to gain further efficacy and safety experience with AMG 701 monotherapy in adult subjects with RRMM.